argenx NV ADR

Yahoo Finance • 7 days ago

High Growth European Tech Stocks To Watch September 2025

The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.03% amid expectations of a U.S. Federal Reserve interest rate cut, signaling optimism in the region's economic outlook despite some mixed si... Full story

Yahoo Finance • 7 days ago

FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations

Expansion of partnership broadens argenx’ manufacturing capabilities in the U.S., supporting its strategy of local-for-local supply of medicines HOLLY SPRINGS, N.C., September 18, 2025--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-l... Full story

Yahoo Finance • 9 days ago

ARGX Quantitative Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology... Full story

Yahoo Finance • 14 days ago

argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. argenx SE is one of them. argenx SE (NASDAQ:ARGX) is strengthening its leadership in autoimmune therapies with the rapid expansion of Vyvga... Full story

Yahoo Finance • 16 days ago

argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy

In the world of growth investing, few strategies have kept their importance as well as the structure presented by Louis Navellier in his 2007 work, "The Little Book That Makes You Rich." The method highlights finding companies showing soli... Full story

Yahoo Finance • 17 days ago

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Shares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study. Continue Reading View Comments... Full story

Yahoo Finance • 29 days ago

argenx to Present at Upcoming Investor Conferences

August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the managem... Full story

Yahoo Finance • 30 days ago

Belgium stocks lower at close of trade; BEL 20 down 0.51%

Investing.com – Belgium stocks were lower after the close on Tuesday, as losses in the Utilities, Industrials and Financials sectors led shares lower. At the close in Brussels, the BEL 20 lost 0.51%. The best performers of the session on... Full story

Yahoo Finance • 30 days ago

European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were lower late Tuesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

Piper Sandler raises argenx stock price target to $820 on Vyvgart success

Investing.com - Piper Sandler has raised its price target on argenx SE (NASDAQ:ARGX) to $820.00 from $750.00 while maintaining an Overweight rating following positive clinical trial results. The company, currently valued at $43.1 billion,... Full story

Yahoo Finance • last month

JPMorgan reiterates Overweight rating on argenx stock after positive trial

Investing.com - JPMorgan has reiterated an Overweight rating and EUR730.00 price target on argenx SE (BR:ARGX) (NASDAQ:ARGX), a $43 billion market cap biotech company with remarkable 88% revenue growth, following positive clinical trial re... Full story

Yahoo Finance • last month

argenx stock rating reiterated at Outperform by RBC on Vyvgart success

Investing.com - RBC Capital has reiterated an Outperform rating on argenx SE (NASDAQ:ARGX) with a price target of $850.00, following positive clinical trial results for the company’s Vyvgart treatment. The $42.3 billion biotech company, wh... Full story

Yahoo Finance • last month

Form 6K argenx NV ADR For: 25 August

... Full story

Yahoo Finance • last month

Argenx stock initiated with Outperform rating by RBC Capital on Vyvgart growth

Investing.com - RBC Capital initiated coverage on argenx SE (NASDAQ:ARGX) with an Outperform rating and a price target of $850.00 on Monday. According to InvestingPro data, the company maintains excellent financial health with a "GREAT" ov... Full story

Yahoo Finance • last month

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Appli... Full story

Yahoo Finance • last month

Belgium stocks higher at close of trade; BEL 20 up 0.26%

Investing.com – Belgium stocks were higher after the close on Friday, as gains in the Telecoms, Technology and Basic Materials sectors led shares higher. At the close in Brussels, the BEL 20 added 0.26% to hit a new all time high. The be... Full story

Yahoo Finance • last month

Earnings call transcript: Argenx Q2 2025 reports robust earnings beat

Argenx NV ADR (ARGX), a biotech company with a market capitalization of $40.09 billion, delivered an impressive earnings performance for Q2 2025, significantly surpassing market expectations. The company’s earnings per share (EPS) were rep... Full story

Yahoo Finance • last month

ARGENX SE - ADR (NASDAQ:ARGX) Ticks Key Boxes for Growth Investors Using Navellier's 'Little Book' Strategy

Growth investing strategies often rely on identifying companies showing strong financial momentum and operational quality. One systematic method for finding these opportunities comes from Louis Navellier’s "The Little Book That Makes You R... Full story

Yahoo Finance • last month

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, tit... Full story

Yahoo Finance • last month

Belgium stocks higher at close of trade; BEL 20 up 0.71%

Investing.com – Belgium stocks were higher after the close on Monday, as gains in the Healthcare, Telecoms and Consumer Services sectors led shares higher. At the close in Brussels, the BEL 20 rose 0.71% to hit a new all time high. The b... Full story